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Abstract
Aims/hypothesis We aimed to determine the association of depression with dementia risk in people with type 2 diabetes, and to
explore the possible mediating role of inflammation in this relationship.
Methods The Edinburgh Type 2 Diabetes Study is a prospective cohort of 1066 men and women with type 2 diabetes aged 60–
75 years. Cox proportional hazards regression analysis was used to investigate the association between depression, assessed at
baseline, and subsequent risk of dementia over 10 years. Depression was defined using the Hospital Anxiety and Depression
Scale, while incident dementia was defined using medical records, prescription data and death certificates. The potential medi-
ating effect of systemic inflammation was assessed by adjusting models for a generalised inflammation factor, derived from four
inflammatory markers measured at baseline (C-reactive protein, IL-6, TNF-α and fibrinogen), and carrying out an exploratory
mediation analysis.
Results Dementia developed in 105 participants over a median follow-up of 10.6 years. After adjusting for age and sex,
depression was associated with over a 2.5-fold increase in risk of dementia (HR 2.59 [95%CI 1.62, 4.15]). Additional adjustment
for the generalised inflammation factor and other covariates did not attenuate the size of association between depression and
incident dementia and mediation analysis showed that it was not a mediator. Adjusted logistic regression models showed cross-
sectional associations of C-reactive protein and IL-6 with depression.
Conclusions/interpretation Depression is an important risk factor for dementia in people with type 2 diabetes. Some inflamma-
tory markers were associated with depression, but systemic inflammation does not appear to mediate the relationship between
depression and dementia.
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CRP C-reactive protein
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ET2DS Edinburgh Type 2 Diabetes Study
HADS Hospital Anxiety and Depression Scale
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MCI Mild cognitive impairment
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SIMD Scottish Index of Multiple Deprivation
Introduction
People with type 2 diabetes are 60% more likely to develop
dementia compared with people in the general population [1].
Identifying and treating potentially modifiable risk factors in
people with type 2 diabetes while they are cognitively healthy
can help reduce cognitive morbidity in later life.
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Late-life depression is a recognised risk factor for dementia in
the general population [2]. In people with diabetes, a small
number of studies with limited follow-up have also suggested
depression is associated with increased risk of dementia [3–5]. It
appears that in people with both diabetes and depression, the
increased risk of dementia and cognitive decline is greater than
the additive effect of the increased risk seen in people with only
diabetes or only depression, suggesting the diseases may have a
synergistic effect on dementia risk when they coexist [4, 6]. As
depression is up to twice as common in people with type 2
diabetes than in the general population, this could have signifi-
cant consequences from a public health perspective [7, 8].
The mechanisms that could explain the increase in dementia
risk associated with coexistent depression and diabetes are
unknown. In people with diabetes, depression is associated with
increased prevalence of micro- and macrovascular disease [9,
10], poor glycaemic control [11] and unhealthy lifestyle behav-
iours such as physical inactivity, smoking and medication non-
adherence [12]. However, after adjusting for these potential inter-
mediate risk factors, people with both depression and diabetes
still have approximately double the risk of dementia compared
with people with only diabetes [3–5].
This increased risk of dementia could be due to inflammation,
a biological mechanism important in the pathophysiologies of
depression, type 2 diabetes and dementia. The presence of a
sustained immune response is viewed as one of the main
pathogenic mechanisms for both Alzheimer’s disease [13] and
vascular dementia [14]. In the general population, associations
have been found between concentrations of several inflammato-
ry markers and increased risk of all-cause dementia [15].
Markers of inflammation have also been strongly associatedwith
the presence and progression of depression [16], while anti-
inflammatory medications may improve antidepressant treat-
ment effects [17]. Raised circulating inflammatory markers have
been associated with increased risk of type 2 diabetes [18], as
well as with depressive symptoms [19] and cognitive decline
[20, 21], in this group. Inflammatory mediators may therefore
have an important role in the development of dementia in people
with both depression and type 2 diabetes. This may be due to the
hostile neural environment created when these conditions coex-
ist, either via a direct effect of inflammatory markers on the
brain, or indirectly through the development of vascular disease.
We conducted a prospective cohort study in an older cohort
of people with type 2 diabetes to investigate the association
between depression and dementia risk and the potential medi-
ating role of inflammation.
Methods
Study population Recruitment and examination in the
Edinburgh Type 2 Diabetes Study (ET2DS) have been
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reported previously [22]. In brief, in 2006/2007 a cohort of
1066 men and women aged 60–75 years living with type 2
diabetes in the Lothian region of Scotland were selected from
a population-based diabetes registry to attend baseline clinics
where they underwent clinical assessment, including for
diabetic retinopathy. Participants were invited to attend year
4 and year 10 follow-up clinics, and non-attenders were
followed up through postal questionnaires and linkage to
medical records. All participants gave written informed
consent and ethical approval was granted by the Lothian
Medical Research Ethics Committee.
Depression The self-completed Hospital Anxiety and
Depression Scale (HADS) was used to measure depression
status [23]. Compared with depression identified by clinical
interview, a depression subscale (HADS-D) score ≥8 has a
sensitivity of 0.82 and a specificity of 0.74, and a score ≥11
a sensitivity of 0.56 and specificity of 0.92, for detecting cases
of major depressive disorder [24]. For the main analysis a
baseline HADS-D score ≥8 was used to define depression.
Sensitivity analyses were also performed using: (1) HADS-
D score ≥11 (severe depression); (2) HADS-D score ≥8 at
both baseline and year 4; and (3) either baseline HADS-D
score ≥8 or an antidepressant prescription (fluoxetine hydro-
chloride, citalopram hydrochloride, paroxetine hydrochloride,
sertraline hydrochloride, fluvoxamine maleate, escitalopram,
isocarboxazid, moclobemide, mianserin, nefazodone hydro-
chloride, mirtazapine, venlafaxine, reboxetine, duloxetine
hydrochloride or agomelatine). Tricyclic antidepressants were
not included due to their frequent use for insomnia and neuro-
pathic pain.
Dementia Incident all-cause dementia was identified through
multiple sources: ICD-10 dementia codes from hospital
admissions (1981 up to 2015, Scottish Morbidity Record-1
scheme); NHS Lothian electronic medical records system
(Trakcare), which contained records of lifetime clinical
dementia diagnosis (searched November 2017 to February
2018); death certificate records of dementia as primary or
secondary cause of death (examined February 2018); and
prescription data for dementia medication. A formal diagnosis
of dementia required at least two of these criteria to be met or
one of the criteria and one other indicator collected at the
research clinics (year 4 or year 10 Mini Mental State Exam
score ≤24, a self- or carer-reported dementia diagnosis or a
GP-reported dementia diagnosis).
Inflammatory markers Venous blood samples were assayed
for plasma C-reactive protein (CRP), IL-6, TNF-α and fibrin-
ogen at the University Department of Medicine, Glasgow
Royal Infirmary. CRP was assayed using a high-sensitivity
immunonephelometric assay (detection limit 0.1 mg/l) and
TNF-α (detection limit 0.1 pg/ml) and IL-6 antigen levels
were assayed using high-sensitivity ELISA kits (R&D
Systems, Oxon, UK). Left-censored values for CRP (n = 13)
and TNF-α (n = 21) (below the minimum detection threshold)
were replaced with values equal to half the minimum detected
value. No values were right censored. Due to risk of acute
infection, participants with CRP >10mg/l were excluded from
primary analyses involving inflammatory marker data but
were included in a sensitivity analysis [25]. As the four
inflammatory markers were highly correlated, we derived a
single generalised inflammation factor based on the first prin-
cipal component of a principal component analysis. For this,
CRP, IL-6 and TNF-α were log-transformed as they had
skewed distributions. The generalised inflammation factor
explained 44.2% of the variance in the inflammatory marker
data.
Additional covariates The presence of macrovascular disease
was accepted if participants had a history of myocardial ischae-
mia, angina, stroke or transient ischaemic attack, as detailed
previously [22]; hypertension was defined as systolic blood
pressure >140 mmHg, diastolic blood pressure >90 mmHg or
anti-hypertensive medication, and dyslipidaemia as total serum
cholesterol >7.5 mmol/l or a lipid-lowering medication.
Baseline prescription data were used to identify prescribed
medicines that could potentially have anti-inflammatory effects
(statins, fibrates, systemic steroids, non-steroidal anti-inflamma-
tory medications and anti-thrombotic medications).
Data analysis Unadjusted statistical analyses were conducted
using Student’s t test for normally distributed continuous data,
the Mann–Whitney U test for non-normally distributed
continuous data and the χ2 test for categorical data.
Spearman’s rank correlation analysis was used to investigate
the associations between inflammatory marker concentrations
and continuous HADS-D score. Inflammatory markers with
skewed distributions (CRP, IL-6 and TNF-α) were log-
transformed and analysed using logistic regression models to
assess the association between each inflammatory marker and
depression status, adjusting for age, sex, prescribed medica-
tions and BMI. Cox proportional hazards (PH) models were
used to investigate the association between depression and
incident dementia. Participants contributed at-risk time from
their baseline clinic date. Data were censored at dementia
diagnosis, death or study endpoint (1 January 2018, the mid-
point of the Trakcare search period). As Cox PH models
require exact dates, but only the year of diagnosis was avail-
able for dementia diagnoses identified through Trakcare, 1
July was imputed as the mid-year point for Trakcare dementia
diagnosis dates. Date of dementia diagnosis was then taken as
the earliest date that dementia was identified from ICD-10
codes, Trakcare or death certificates. If the exact ICD-10 diag-
nosis date and Trakcare year of diagnosis were in the same
year, the ICD-10 date was used. Multivariable Model 1 was
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adjusted for age and sex. Multivariable Model 2 was addition-
ally adjusted for the generalised inflammation factor.
Multivariable Model 3 was adjusted for: age, sex, marital
status, education status, employment status, Scottish Index
of Multiple Deprivation (SIMD), BMI, smoking, hyperten-
sion, dyslipidaemia, macrovascular disease, prescribed medi-
cations, diabetic retinopathy, diabetes duration, diabetesmedi-
cation and HbA1c. Multivariable Model 4 included the same
covariates as Multivariable Model 3 with the addition of the
generalised inflammation factor. To minimise the risk of
early-stage dementia being misdiagnosed as depression, sensi-
tivity analyses were carried out where a dementia diagnosis
time lag was applied, such that dementia cases diagnosed
between baseline and year 2, and baseline and year 4, were
excluded from the analysis.
Mediation analysis The potential mediating role of inflamma-
tion was assessed using two methods. First, the causal steps
method was used [26]. In this method, X (depression) indi-
cates the independent variable, Y (dementia) indicates the
dependent variable and M (generalised inflammation factor)
indicates the mediator (see electronic supplementary material
[ESM] Fig. 1). Partial mediation is considered to have
occurred if: (1) X is related to Y; (2) X is related to M; (3) M
is related to Y after adjusting for X; and (4) the association
between X and Y is significantly decreased after adjusting for
M. As the dementia variable contained censored data, accel-
erated failure time models were used to assess the relationship
between: (1) depression and dementia; and (2) inflammation
and dementia [27], and a linear regression model was used to
assess the effect of depression on inflammation. Second,
mediation was assessed using the bootstrapping method so
that the percentage of the association between depression
and dementia mediated by the generalised inflammation factor
could be estimated [28].
Competing risk of death Due to the advanced age of the
cohort, large numbers of participants may have died before
dementia could be diagnosed. As competing risk of death is
not accounted for in standard Cox PH models, this has the
potential to lead to an overestimation of the effect size [29].
The effect of this was investigated with a competing risk
regression (CRR) model [30].
Results
Baseline characteristics A total of 1066 people were enrolled
in the ET2DS. Of these, two participants were excluded from
further analysis; one as they had dementia at baseline
(applying the same criteria as used during follow-up) and the
second as illness prevented them from completing the HADS.
Of the remaining 1064 participants, 62 had CRP
concentrations >10 mg/l that were excluded from analyses
involving inflammatory marker data. Depression (HADS-D
≥8) was present in 126 participants and severe depression
(HADS-D ≥11) in 28. Participants with depression were more
likely to be female, to be single or widowed, and to live in the
most deprived quintile of socioeconomic deprivation
(Table 1). They were also more likely to have a higher BMI,
to smoke, to have macrovascular disease, to manage their
diabetes with insulin and to have a higher mean HbA1c.
Anxiety (HADS anxiety subscale [HADS-A] ≥ 8) was present
in 99 participants (78.6%) with depression.
Associations of inflammatory mediators with depression at
baseline Spearman’s Rank correlation analysis showed weak
but statistically significant associations with all inflammatory
marker concentrations and continuous HADS-D score
(Table 2). Of the 1002 participants with non-raised CRP
concentrations, 116 had depression and 24 severe depression.
Univariate logistic regression models, where depression status
was the dependent variable, showed statistically significant
associations with fibrinogen, IL-6, CRP and the generalised
inflammation factor, but not with TNF-α. When the models
were adjusted for age, sex, BMI and medications, the associ-
ation of fibrinogen with depression was no longer statistically
significant. When severe depression was used as the depen-
dent variable and the same covariates were adjusted for, a
statistically significant association was found with CRP (OR
2.21 [95% CI 1.29, 4.05]) and the generalised inflammation
factor (OR 1.57 [95% CI 1.11, 2.23]), but not with fibrinogen
(OR 1.34 [95% CI 0.73, 2.44]), IL-6 (OR 1.74 [95% CI 0.90,
3.25]) or TNF-α (OR 1.60 [95% CI 0.91, 2.82]).
Dementia incidence, association with depression and possi-
ble mediation by inflammation Over a median follow-up of
10.6 years (IQR 8.4–11.0), 105 participants developed demen-
tia. Participants who developed dementia were older (69.4 vs
67.7 years), more likely to be male (61% vs 50.3% male) and
more likely to have depression (21.0% vs 10.8%) compared
with those without dementia. Diabetes treatment and glycaemic
control were similar across both groups, but those with demen-
tia had a higher prevalence of diabetic retinopathy (42.2% vs
31.5%) and macrovascular disease (42.9% vs 34.2%) (ESM
Table 1). Most cases of dementia were diagnosed in the depres-
sion group from around year 6 of follow-up onwards (Fig. 1).
During follow-up there were 317 deaths, and, of these, 41
deaths were in participants that had developed dementia. The
age- and sex-adjusted Cox PH model showed that depression
was associated with over a 2.5-fold increased risk of dementia
(HR 2.59 [95% CI 1.62, 4.15]). Additional adjustment for the
generalised inflammation factor and other covariates did not
significantly change the effect size (Table 3). In sensitivity
analyses, changing the depression case definitions also did not
substantially change the observed effect (ESM Table 2),
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Table 1 Baseline characteristics of study participants by depression status
Variable Total cohort (N = 1064) With depression (n = 126)a Without depression (n = 938) p value
Mean age, years (SD) 67.9 (4.2) 67.4 (4.2) 68.0 (4.2) 0.170
Sex, n (%)
Male 546 (51.3) 50 (39.7) 496 (52.9) 0.005
Female 518 (48.7) 76 (60.3) 442 (47.1)
Marital status, n (%)
Married/living with long-term partner 796 (75.0) 84 (66.7) 712 (76.1) 0.036
Single 159 (15.0) 22 (17.5) 137 (14.6)
Widowed 107 (10.1) 20 (15.9) 87 (9.3)
Highest level of educational attainment, n (%)
University/college 171 (16.1) 16 (12.7) 155 (16.5) 0.196
Other professional/technical qualification 305 (28.7) 31 (24.6) 274 (29.2)
Primary/secondary school 588 (55.3) 79 (62.7) 509 (54.3)
Current employment status, n (%)
Full/part-time employment 152 (14.3) 10 (7.9) 142 (15.1) 0.047
Retired 862 (81.0) 107 (84.9) 755 (80.5)
Unemployed/homemaker/other 50 (4.7) 9 (7.1) 41 (4.4)
SIMD quintile, n (%)
First (most deprived) 127 (11.9) 24 (19.0) 103 (11.0) 0.086
Second 207 (19.5) 23 (18.3) 184 (19.6)
Third 188 (17.7) 21 (16.7) 167 (17.8)
Fourth 194 (18.2) 21 (16.7) 173 (18.4)
Fifth (least deprived) 348 (32.7) 37 (29.4) 311 (33.2)
HADS-A score ≥8, n (%)
Yes 321 (30.2) 99 (78.6) 222 (23.7) <0.001
No 743 (69.8) 27 (21.4) 716 (76.3)
Median HADS-A score (IQR) 5.0 (5.0) 10.0 (5.0) 5.0 (4.0) <0.001
Median HADS-D score (IQR) 3.0 (5.0) 9.0 (2.0) 3.0 (4.0) <0.001
Mean BMI (SD) 31.4 (5.7) 33.3 (6.6) 31.2 (5.5) <0.001
Smoking status, n (%)
Smoker 153 (14.4) 27 (21.4) 126 (13.4) 0.016
Non-smoker/ex-smoker 911 (85.6) 99 (78.6) 812 (86.6)
Hypertension, n (%)
Yes 917 (86.3) 111 (88.1) 806 (86.1) 0.543
No 145 (13.7) 15 (11.9) 130 (13.9)
Dyslipidaemia, n (%)
Yes 913 (86.1) 110 (88.0) 803 (85.8) 0.503
No 148 (13.9) 15 (12.0) 133 (14.2)
Macrovascular disease, n (%)
Yes 373 (35.1) 63 (50.0) 310 (33.0) <0.001
No 691 (64.9) 63 (50.0) 628 (67.0)
Diabetic retinopathy, n (%)
Yes 339 (32.5) 43 (34.7) 296 (32.2) 0.582
No 704 (67.5) 81 (65.3) 623 (67.8)
Median time since diabetes diagnosis, years (IQR) 6.0 (8.0) 7.0 (8.0) 6.0 (8.0) 0.784
Diabetes treatment, n (%)
Diet only 198 (18.6) 23 (18.3) 175 (18.7) 0.009
Diet + oral tablets 680 (64.0) 69 (54.8) 611 (65.2)
Diet ± oral tablets + insulin 185 (17.4) 34 (27.0) 151 (16.1)
Mean HbA1c, mmol/mol (SD) 57.5 (12.3) 59.8 (14.7) 57.2 (11.9) 0.027
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including when the 2 year and 4 year dementia diagnosis time
lags were applied. The age- and sex-adjusted HR when the
independent variable was severe depression was 4.40 (95%
CI 1.88, 10.26), and 4.39 (95% CI 2.37, 8.15) when it was
depression, at baseline and year 4.
Mediation analysis The causal steps regression analyses showed
that depression was positively associated with higher levels of
inflammation (β: 0.57, p < 0.001) (ESM Fig. 1). Depression was
associated with having a 0.65 times shorter time period before
developing dementia without adjusting for inflammation
(p < 0.01), and a 0.66 times shorter time period when inflamma-
tion was adjusted for (p < 0.01). However, the association
between inflammation and dementia was non-significant when
depression was adjusted for (p = 0.777), indicating that inflam-
mation did not mediate the association between depression and
dementia. Mediation analysis using bootstrapping with 5000
replications also showed that inflammation was not a mediator,
accounting for only 1.7% (95% CI −13, 19) of the association
between depression and dementia (ESM Table 3).
Competing risk analysis The age- and sex-adjusted CRR
model showed that depression had a similar effect size (HR
2.24 [95% CI 1.40, 3.60]) to dementia risk when compared
with the standard Cox PH model.
Sensitivity analyses In total, 49 participants were prescribed an
antidepressant. Of these, 16 had a HADS-D score ≥8 and 33 a
HADS-D score <8. Incorporating the antidepressant data into
the depression case definition therefore increased the number
of cases to 159. Re-analysing the data using this definition of
depression did not change any of the main findings, nor did
including the inflammatory marker data from the 62 partici-
pants that had a raised CRP (data not shown).
Discussion
Principal findings The prospective association between
depression and dementia was investigated in a cohort of older
people with type 2 diabetes. We found that depression in later
life, after adjusting for age and sex, was associated with over a
2.5-fold increase in dementia risk. The relationship remained
constant in a series of sensitivity analyses where different
criteria were used to define depression. Cross-sectional asso-
ciations of inflammatory markers with depression status were
Table 2 Association between inflammatory markers and depression
Inflammatory marker Spearman’s Rank
correlation coefficienta, ρ
Unadjusted logistic regression
modelb, OR (95% CI)
Adjusted logistic regression
modelc, OR (95% CI)
Fibrinogen 0.109 (p < 0.001) 1.45 (1.09, 1.92) 1.33 (0.99, 1.79)
IL-6 0.147 (p < 0.001) 1.59 (1.19, 2.11) 1.59 (1.17, 2.15)
TNF-α 0.067 (p = 0.034) 1.13 (0.89, 1.46) 1.11 (0.86, 1.44)
CRP 0.161 (p < 0.001) 1.58 (1.29, 1.97) 1.59 (1.17, 2.15)
Generalised inflammation factor 0.176 (p < 0.001) 1.38 (1.19, 1.61) 1.35 (1.15, 1.59)
a Association between inflammatory marker concentration and continuous HADS-D score
b Association between inflammatory marker concentration and depression (HADS-D≥8)
c Association between inflammatory marker concentration and depression (HADS-D≥8). Adjusted for age, sex, BMI, lipid-lowering medications, non-
steroidal anti-inflammatory drugs (NSAIDs), anti-thrombotic medication and systemic steroids
Table 1 (continued)
Variable Total cohort (N = 1064) With depression (n = 126)a Without depression (n = 938) p value
Mean HbA1c, % (SD) 7.4 (1.1) 7.6 (1.3) 7.4 (1.1) 0.027
Mean fibrinogen, g/l (SD) 3.6 (0.7) 3.7 (0.7) 3.6 (0.7) 0.009
Median IL-6, pg/ml (IQR) 2.8 (2.3) 3.4 (2.6) 2.7 (2.2) 0.001
Median TNF-α, pg/ml (IQR) 1.1 (0.9) 1.2 (0.9) 1.1 (0.9) 0.258
Median CRP, mg/l (IQR) 1.7 (2.8) 2.8 (5.2) 1.6 (2.6) <0.001
Mean generalised inflammation factor (SD) 0.0 (1.3) 0.5 (1.3) −0.1 (1.3) <0.001
p values calculated by χ2 test for categorical variables, Student’s t test for normally distributed continuous data and Mann–Whitney U test for non-
normally distributed continuous data, comparing the groups with and without depression. Missing or incomplete values were as follows: CRP=24 cases;
TNF-α=3 cases; fibrinogen=3 cases; IL-6=2 cases; diabetic retinopathy=21 cases; diabetes duration=13 cases; HbA1c=9 cases; BMI=3 cases; marital
status=2 cases; hypertension status=2 cases; dyslipidaemia status=2 cases
a HADS-D score ≥8
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tested and showed positive associations with IL-6 and CRP.
To explore whether systemic inflammation had a role as a
mediator in the relationship between depression and dementia,
models were adjusted for a generalised inflammation factor,
derived from four inflammatory markers measured at
baseline, and a mediation analysis was undertaken.
Adjusting for the generalised inflammation factor did not
substantially change the effect size between depression and
dementia, and mediation analysis found no evidence of medi-
ation. Adjusting for other potentially important risk factors,
including smoking, obesity, hypertension, vascular disease
and HbA1c, also did not substantially alter the effect size
between depression and dementia.
Strengths and weaknessesA strength of this study was that we
were able to use a well-characterised cohort of participants with
type 2 diabetes that had inflammatory markers measured at
baseline. The cohort was also relatively homogenous in terms
of age, ethnicity and glycaemic control, meaning these potential
confounders were unlikely to influence our results. Another
strength was that through using multiple data collection
methods we were able to follow up our cohort prospectively
for 10 years with minimal loss to follow-up. The study also had
a number of limitations. First, our method of identifying
dementia relied on the analysis of collected medical data which
were reliant on accurate clinical diagnosis and reporting. Some
participants with dementia may have accessed health care infre-
quently and some may have died before a diagnosis could be
made. The effect of competing risk of death was investigated
with a CRR analysis, which showed that the effect of this was
likely to be small. Furthermore, due to their similar clinical
presentations, some clinicians may have incorrectly diagnosed
depression as dementia. The same problem may have resulted
in some cases of early-stage dementia being misdiagnosed as
depression. This is further complicated by evidence that
suggests late-life depression can be a prodrome of dementia
for several years before dementia develops [31]. As the effect
of depression on incident dementia in our cohort became appar-
ent after year 6 of follow-up, it appears likely that we were
successful in being able to separately identify cases of depres-
sion and dementia. Another limitation of our depression defini-
tion was that it was only measured at baseline so the effect of
duration of depressive symptoms could not be evaluated. To
attempt to address these issues, sensitivity analyses were carried
out where the time between depression diagnosis and dementia
was increased to minimise the risk of dementia being
misdiagnosed as depression, and different depression case defi-
nitions were used that incorporated antidepressant medications
and depression at year 4. Ideally, depression would have been
identified by clinical interview, earlier in the life course and
measured repeatedly. And, ideally, repeated measurements of
inflammatory markers would also have been incorporated into
the analysis, rather than measurements from a single time point
as used in this analysis, to more effectively identify participants
with long-term increased levels of systemic inflammation.
Finally, although associations were adjusted for a wide range
of important risk factors, the independence of the relationships
from additional potential risk factors for dementia in people
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Fig. 1 Kaplan–Meier curves of dementia-free survival probability by
follow-up time, stratified by depression status (HADS-D≥8). Displayed
below are the corresponding number at risk and cumulative events tables
Table 3 Association between baseline depression and incident
dementia
Model HR (95% CI)
Unadjusted 2.35 (1.47, 3.77)
Multivariable Model 1a 2.59 (1.62, 4.15)
Multivariable Model 2b 2.34 (1.41, 3.89)
Multivariable Model 3c 2.54 (1.51, 4.26)
Multivariable Model 4d 2.37 (1.37, 4.10)
a Adjusted for age and sex; number in model = 1064; number of
events=105
bAdjusted for age, sex and generalised inflammation factor; number in
model=1002; number of events=99
c Adjusted for age, sex, marital status, education status, employment
status, SIMD, BMI, smoking, hypertension, dyslipidaemia,
macrovascular disease, prescribed medications, diabetic retinopathy,
diabetes duration, diabetes medication and HbA1c; number in
model=114; number of events=99
d Adjusted for age, sex, marital status, education status, employment
status, SIMD, BMI, smoking, hypertension, dyslipidaemia,
macrovascular disease, prescribed medications, diabetic retinopathy,
diabetes duration, diabetes medication, HbA1c and generalised inflamma-
tion factor; number in model=955; number of events=93
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with type 2 diabetes, for example, genetic susceptibility, anxi-
ety and hypoglycaemia, would require further in-depth analy-
sis. The generalisability of our study is limited due to the study
population being derived from a single geographical region
with access to a well-developed national healthcare system.
Comparison with other studiesDepression is a recognised risk
factor for dementia in the general population [2, 31], but in
studies of cohorts exclusively comprising of people with diabe-
tes, a group at higher risk of dementia than the general popula-
tion, the effect of depression on dementia risk has only been
investigated in two 5 year prospective cohort studies and one
large retrospective study, which all have the same authorship
[3–5]. Each study found coexistent depression in people with
diabetes to be associated with an approximately twofold
increase in dementia risk. The larger effect size found in the
present study may be related to the longer period of follow-up.
In keeping with the findings of the previous studies, no attenu-
ation in effect size was found after adjusting for important clin-
ical and social covariates. Prior studies were unable to include
adjustment for inflammation, which has been suggested as a
biological mechanism that could mediate the development of
dementia in people with both type 2 diabetes and depression
[3–5, 32]. We did not find any evidence to support this hypoth-
esis. This is in contrast to a cross-sectional study that investi-
gated the association of inflammatory markers with mild cogni-
tive impairment (MCI) in people with type 2 diabetes and
coexisting depression. It found CRP, IL-6 and TNF-α to be
associated with increased risk of MCI [21]. We found cross-
sectional associations of depression status with raised inflam-
matory marker concentrations. When assessed as a continuous
variable, associations were found between HADS-D score and
all measured inflammatory markers, but when analysed as a
binary variable in adjusted models, associations were only
found with CRP and IL-6. This is partially in keeping with
the results of prior studies, which are low in number and mostly
have small sample sizes [19]. The most commonly measured
inflammatory marker has been CRP, which, in keeping with
our findings, has been found to be associated with depression in
people with both type 2 diabetes and depression [33–36]. Only
one prior study that measured IL-6 found an association with
IL-6 and depression in people with type 2 diabetes [33], where-
as two studies did not [34, 36]. Two studies, one of which
consisted of over 1200 adults with newly diagnosed type 2
diabetes, measured TNF-α concentrations [33, 34]. Both, in
keeping with the results of our adjusted logistic regression anal-
ysis, did not find an association between TNF-α and depres-
sion. Only one study measured fibrinogen and found it to be
raised in people with both type 2 diabetes and depression
compared with those with diabetes alone [37]. Of note, different
depression scoring systems were used between studies and this
has been shown previously to affect associations found with
specific inflammatory markers [38].
Study meaning and implications In people with type 2
diabetes, a single episode of depressive symptoms in later
life places them at high risk of later developing dementia.
It appears that this relationship is not due to unhealthy
lifestyle behaviours, diabetic severity or cardiovascular
comorbidity, but rather a feature of the presence of depres-
sive symptoms. Sensitivity analyses suggested that depres-
sion severity and duration may be associated with higher
dementia risk but, as one would expect given the smaller
sample sizes used for these analyses, the confidence inter-
vals were wide and overlapped with those of the primary
analysis, so this has to be interpreted with caution. We did
not find any evidence to suggest that inflammation, as
measured by a derived generalised inflammation factor,
was responsible for mediating this relationship. The rela-
tionship could be explained by hypothalamic–pituitary–
adrenal axis dysregulation and increased insulin resistance,
both of which are pathways associated with depression and
have been linked to the development of cognitive impair-
ment [39, 40]. The association may also be partially
explained by anxiety, which was prevalent in our cohort
and has been shown to be a risk factor for dementia in the
general population [41]. As a potentially modifiable risk
factor, clinicians should regard effectively screening for,
diagnosing and treating depression as a mainstay of the
management of dementia risk in people that have type 2
diabetes. Our study shows that the HADS questionnaire
may be a useful screening tool in this population. Our
study showed that some inflammatory markers, especially
CRP and IL-6, appeared to be associated with depression
status. This could be due to both depression and diabetes
being inflammatory conditions and may explain some of
the increased risk of complications other than dementia for
people with diabetes and comorbid depression.
Unanswered questions and future research As the burden of
type 2 diabetes and depression on individuals and society
continues to grow, further research is required to investigate
the pathophysiological pathways that link these diseases with
each other and with dementia. This will require the temporal
association of the diseases to be evaluated in studies than can
incorporate repeated measurements of depression, diabetes
and dementia across the life course. Although our results
suggest that inflammation is not an important part of this path-
way, with only four inflammatory markers measured at one
time point, analyses involving serial measurements of inflam-
matory markers are required. The prognostic significance of
depression severity and duration on dementia risk, and the
relationship of depression with anxiety, also requires further
evaluation. The significance of raised CRP and IL-6 in people
with both depression and type 2 diabetes is unclear and may
be important in the development of other diabetes-related
complications.
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ConclusionWe conclude that in a representative cohort of older
people with type 2 diabetes, depression was associated with
increased subsequent risk of developing dementia. As a poten-
tially modifiable risk factor, treating depression should be
considered a high priority in the management of dementia risk
in people with type 2 diabetes. Our findings do not support the
hypothesis that systemic inflammation is an important pathway
that mediates this association, and further work is required to
determine the underlying pathophysiological pathways.
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